Literature DB >> 25937773

Progression of targeted therapy in advanced cholangiocarcinoma.

Yingying Huang1, Xiaomei Li1, Yunbo Zhao1.   

Abstract

It is necessary to establish an effective therapy to improve the survival of patients with advanced cholangiocarcinoma (CCA). Recently, with the development of pathology research in CCA, a lot of special bio-markers such as EGFR, VEGF, HER2, and MEK et al. could be over expression or mutations in CCA patients. According to their changes, combinations of targeted therapy plus chemotherapy are now recognized as effective therapies for advanced CCA. The aim of this paper is to analyze recent promising studies about targeted therapy alone or combination with each other or with chemotherapies.

Entities:  

Keywords:  Cholangiocarcinoma (CCA); advanced tumor; combined therapy; molecular targeted therapy; tumor therapy

Year:  2015        PMID： 25937773      PMCID： PMC4409969          DOI： 10.3978/j.issn.1000-9604.2015.04.01

Source DB:  PubMed          Journal:  Chin J Cancer Res        ISSN： 1000-9604            Impact factor:   5.087


  32 in total

1.  Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers.

Authors:  Tanios Bekaii-Saab; Mitch A Phelps; Xiaobai Li; Motoyasu Saji; Laura Goff; John Sae Wook Kauh; Bert H O'Neil; Stephanie Balsom; Catherine Balint; Ryan Liersemann; Vasily V Vasko; Mark Bloomston; William Marsh; L Austin Doyle; Gilian Ellison; Michael Grever; Matthew D Ringel; Miguel A Villalona-Calero
Journal:  J Clin Oncol       Date:  2011-04-25       Impact factor: 44.544

2.  Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study.

Authors:  Birgit Gruenberger; Johannes Schueller; Ute Heubrandtner; Fritz Wrba; Dietmar Tamandl; Klaus Kaczirek; Rudolf Roka; Sandra Freimann-Pircher; Thomas Gruenberger
Journal:  Lancet Oncol       Date:  2010-11-09       Impact factor: 41.316

3.  Phase II study of erlotinib in patients with advanced biliary cancer.

Authors:  Philip A Philip; Michelle R Mahoney; Cristine Allmer; James Thomas; Henry C Pitot; George Kim; Ross C Donehower; Tom Fitch; Joel Picus; Charles Erlichman
Journal:  J Clin Oncol       Date:  2006-07-01       Impact factor: 44.544

4.  Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.

Authors:  Juan Valle; Harpreet Wasan; Daniel H Palmer; David Cunningham; Alan Anthoney; Anthony Maraveyas; Srinivasan Madhusudan; Tim Iveson; Sharon Hughes; Stephen P Pereira; Michael Roughton; John Bridgewater
Journal:  N Engl J Med       Date:  2010-04-08       Impact factor: 91.245

5.  Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells.

Authors:  Hajime Isomoto; Shogo Kobayashi; Nathan W Werneburg; Steve F Bronk; Maria Eugenia Guicciardi; David A Frank; Gregory J Gores
Journal:  Hepatology       Date:  2005-12       Impact factor: 17.425

6.  Simultaneous detection of epidermal growth factor receptor (EGF-R), epidermal growth factor (EGF) and ras p21 in cholangiocarcinoma by an immunocytochemical method.

Authors:  A Nonomura; G Ohta; Y Nakanuma; R Izumi; Y Mizukami; F Matsubara; M Hayashi; K Watanabe; N Takayanagi
Journal:  Liver       Date:  1988-06

7.  A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer.

Authors:  Ramesh K Ramanathan; Chandra P Belani; Deepti A Singh; Michael Tanaka; Heinz-Josef Lenz; Yun Yen; Hedy L Kindler; Syma Iqbal; Jeff Longmate; Philip C Mack; Georg Lurje; Regina Gandour-Edwards; Janet Dancey; David R Gandara
Journal:  Cancer Chemother Pharmacol       Date:  2009-01-24       Impact factor: 3.333

8.  Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan.

Authors:  T Okusaka; K Nakachi; A Fukutomi; N Mizuno; S Ohkawa; A Funakoshi; M Nagino; S Kondo; S Nagaoka; J Funai; M Koshiji; Y Nambu; J Furuse; M Miyazaki; Y Nimura
Journal:  Br J Cancer       Date:  2010-07-13       Impact factor: 7.640

9.  Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial.

Authors:  C Bengala; F Bertolini; N Malavasi; C Boni; E Aitini; C Dealis; S Zironi; R Depenni; A Fontana; C Del Giovane; G Luppi; P Conte
Journal:  Br J Cancer       Date:  2009-11-24       Impact factor: 7.640

10.  Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma.

Authors:  D Yoshikawa; H Ojima; A Kokubu; T Ochiya; S Kasai; S Hirohashi; T Shibata
Journal:  Br J Cancer       Date:  2009-03-24       Impact factor: 7.640
View more
  1 in total

1.  Guided chemotherapy based on patient-derived mini-xenograft models improves survival of gallbladder carcinoma patients.

Authors:  Ming Zhan; Rui-Meng Yang; Hui Wang; Min He; Wei Chen; Sun-Wang Xu; Lin-Hua Yang; Qiang Liu; Man-Mei Long; Jian Wang
Journal:  Cancer Commun (Lond)       Date:  2018-07-17
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.